Sysmex Corporation ADR (OTCMKTS:SSMXY – Get Free Report)’s stock price reached a new 52-week high during trading on Thursday. The stock traded as high as $13.01 and last traded at $13.01, with a volume of 6,074 shares. The stock had previously closed at $12.1850.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised shares of Sysmex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. Two investment analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.
Read Our Latest Report on SSMXY
Sysmex Price Performance
The company has a current ratio of 3.40, a quick ratio of 2.53 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $7.82 billion, a price-to-earnings ratio of 30.62 and a beta of 1.20. The business has a 50-day moving average price of $11.94 and a two-hundred day moving average price of $9.98.
Sysmex (OTCMKTS:SSMXY – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.02. Sysmex had a return on equity of 8.01% and a net margin of 7.62%. The company had revenue of $825.85 million during the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, research analysts forecast that Sysmex Corporation ADR will post 0.41 EPS for the current year.
About Sysmex
Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and distributes clinical laboratory instruments, reagents and related information systems. Its products are used by hospitals, diagnostic laboratories and other healthcare providers to support the analysis of blood, urine and other biological samples.
The company is best known for its hematology analyzers, which help laboratories evaluate blood cells and identify conditions such as anemia and leukemia.
Featured Stories
- Five stocks we like better than Sysmex
- The Fed Is Split on Rates—Why These 2 Treasury ETFs Could Have an Edge
- Gold’s 2026 Pullback Raises a Bigger Question: Buy the Metal or the Miners?
- Matador Resources Insider Buying and the Case for a Dividend Stock Rebound
- Datadog’s Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight?
Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.
